Elisaf M, Kalaitzidis R, Siamopoulos K C
Department of Internal Medicine, University of Ioannina Medical School, Greece.
Nephron. 1998;79(3):337-9. doi: 10.1159/000045059.
Pamidronate constitutes a major advance in the treatment of tumor-associated hypercalcemia. However, transient electrolyte abnormalities have been reported after pamidronate administration. We describe here a patient with multiple myeloma and severe hypercalcemia who developed transient but significant electrolyte disturbances (mainly hypophosphatemia and hypomagnesemia) after a single dose of 90 mg of pamidronate, focusing on the underlying pathophysiological mechanisms.
帕米膦酸盐在肿瘤相关性高钙血症的治疗方面取得了重大进展。然而，已有报道称帕米膦酸盐给药后会出现短暂的电解质异常。我们在此描述一名患有多发性骨髓瘤和严重高钙血症的患者，该患者在单次静脉注射90毫克帕米膦酸盐后出现了短暂但显著的电解质紊乱（主要是低磷血症和低镁血症），并着重探讨其潜在的病理生理机制。
Zotero 插件